Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases

Aikawa, Nádia E.; Balbi, Verena; Borba, Eduardo Ferreira; Tonacio, Adriana Coracini; Sallum, Adriana Maluf Elias; Campos, Lúcia Maria Arruda; Kozu, Kátia; Vendramini, Margarete Borges Galhardo; Fontoura, Nicole; Azevedo, Adriana de Souza; Schwarcz, Waleska Dias; Sartori, Ana Marli Christovam; Antonângelo, Leila; Silva, Clóvis A.; Bonfá, Eloísa

doi:10.1016/j.jvacx.2021.100131

Cited by 8 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical trials have identified similar viremia and immunogenic responses between the doses. No serious adverse events were identified in these studies, although the sample size was too small for a safety evaluation (27)(28)(29)(30)(31)(32).…”

Section: Discussionmentioning

confidence: 98%

Yellow Fever Vaccine–Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil

Fernandes¹,

Pôrto²,

Oliveira³

et al. 2023

Emerg. Infect. Dis.

View full text Add to dashboard Cite

We describe 5 cases of yellow fever vaccine–associated viscerotropic disease (YEL-AVD) in 2 familial clusters during the 2017–2018 yellow fever (YF) vaccination campaign in São Paulo state, Brazil. The first case was that of a 40-year-old white man who died of icterohemorrhagic syndrome, which was confirmed to be YEL-AVD by using real-time reverse transcription PCR to detect 17DD YF vaccine in the liver. Ten years previously, his brother died of a clinically similar disease without a confirmed diagnosis 9 days after YF vaccination. The second cluster included 3 of 9 siblings in whom hepatitis developed in the first week after receiving fractionated doses of YF vaccine. Two of them died of hemorrhagic diathesis and renal and respiratory failure, and 17DD-YF vaccine was detected in serum samples from all patients and in the liver in 1 case. Genetic factors might play a substantial role in the incidence of YEL-AVD.

show abstract

Section: Discussionmentioning

confidence: 98%

Yellow Fever Vaccine–Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil

Fernandes¹,

Pôrto²,

Oliveira³

et al. 2023

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…Gelbfieberimpfung) sind kontraindiziert. In 2 kleineren Studien war bei niedriger Methotrexat-Dosis eine Gelbfieberimpfung sicher und führte zu vergleichbarer Seroprotektion 99 , 101 . 12 Orale Impfstoffe können unter Vedolizumab unwirksam sein. …”

Section: Reiseimpfungen Bei Risikogruppenunclassified

Reiseimpfungen – Hinweise und Empfehlungen

Rothe,

Rosenbusch,

Bühler

et al. 2024

Flugmedizin · Tropenmedizin · Reisemedizin - FTR

View full text Add to dashboard Cite

“…Firstly, YF17D appears to be well tolerated in infants and children [210,211] with a reactogenicity and overall sideeffects comparable to other parenterally administered vaccines [212]. Apparently, this does even not exclude more vulnerable individuals that are prone to complications due to (some degree of) immune suppression [213,214]. Notably, a similarly promising safety has been observed in children for chimeric ChimeriVax-JE/Imojev [215], being superior to original live-attenuated JEV vaccine JE Sa14-14-2 [216,217].…”

Section: Box 3 -General Vaccine Safetymentioning

confidence: 99%

YF17D‐based vaccines – standing on the shoulders of a giant

Sanchez‐Felipe,

Alpizar,

et al. 2024

Eur J Immunol

View full text Add to dashboard Cite

SummaryLive‐attenuated yellow fever vaccine (YF17D) was developed in the 1930s as the first ever empirically derived human vaccine. Ninety years later, it is still a benchmark for vaccines made today. YF17D triggers a particularly broad and polyfunctional response engaging multiple arms of innate, humoral and cellular immunity. This unique immunogenicity translates into an extraordinary vaccine efficacy and outstanding longevity of protection, possibly by single‐dose immunization. More recently, progress in molecular virology and synthetic biology allowed engineering of YF17D as a powerful vector and promising platform for the development of novel recombinant live vaccines, including two licensed vaccines against Japanese encephalitis and dengue, even in paediatric use. Likewise, numerous chimeric and transgenic preclinical candidates have been described. These include prophylactic vaccines against emerging viral infections (e.g. Lassa, Zika and SARS‐CoV‐2) and parasitic diseases (e.g. malaria), as well as therapeutic applications targeting persistent infections (e.g. HIV and chronic hepatitis), and cancer. Efforts to overcome historical safety concerns and manufacturing challenges are ongoing and pave the way for wider use of YF17D‐based vaccines. In this review, we summarize recent insights regarding YF17D as vaccine platform, and how YF17D‐based vaccines may complement as well as differentiate from other emerging modalities in response to unmet medical needs and for pandemic preparedness.

show abstract

Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases

Cited by 8 publications

References 24 publications

Yellow Fever Vaccine–Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil

Yellow Fever Vaccine–Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil

Reiseimpfungen – Hinweise und Empfehlungen

YF17D‐based vaccines – standing on the shoulders of a giant

Contact Info

Product

Resources

About